Your browser doesn't support javascript.
loading
Integrated sample inactivation, amplification, and Cas13-based detection of SARS-CoV-2.
Arizti-Sanz, Jon; Freije, Catherine A; Stanton, Alexandra C; Boehm, Chloe K; Petros, Brittany A; Siddiqui, Sameed; Shaw, Bennett M; Adams, Gordon; Kosoko-Thoroddsen, Tinna-Solveig F; Kemball, Molly E; Gross, Robin; Wronka, Loni; Caviness, Katie; Hensley, Lisa E; Bergman, Nicholas H; MacInnis, Bronwyn L; Lemieux, Jacob E; Sabeti, Pardis C; Myhrvold, Cameron.
Affiliation
  • Arizti-Sanz J; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Freije CA; Harvard-MIT Program in Health Sciences and Technology, Cambridge, MA, USA.
  • Stanton AC; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Boehm CK; Program in Virology, Harvard Medical School, Boston, MA, USA.
  • Petros BA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Siddiqui S; Program in Virology, Harvard Medical School, Boston, MA, USA.
  • Shaw BM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Adams G; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Kosoko-Thoroddsen TF; Harvard-MIT Program in Health Sciences and Technology, Cambridge, MA, USA.
  • Kemball ME; Harvard-MIT MD-PhD Program, Boston, MA, USA.
  • Gross R; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Wronka L; Computational and Systems Biology PhD program, MIT, Cambridge, MA, USA.
  • Caviness K; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Hensley LE; Department of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
  • Bergman NH; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • MacInnis BL; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Lemieux JE; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Sabeti PC; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, USA.
  • Myhrvold C; National Biodefense Analysis and Countermeasures Center, Fort Detrick, MD, USA.
bioRxiv ; 2020 May 28.
Article in En | MEDLINE | ID: mdl-32511415
ABSTRACT
The COVID-19 pandemic has highlighted that new diagnostic technologies are essential for controlling disease transmission. Here, we develop SHINE (SHERLOCK and HUDSON Integration to Navigate Epidemics), a sensitive and specific integrated diagnostic tool that can detect SARS-CoV-2 RNA from unextracted samples. We combine the steps of SHERLOCK into a single-step reaction and optimize HUDSON to accelerate viral inactivation in nasopharyngeal swabs and saliva. SHINE's results can be visualized with an in-tube fluorescent readout - reducing contamination risk as amplification reaction tubes remain sealed - and interpreted by a companion smartphone application. We validate SHINE on 50 nasopharyngeal patient samples, demonstrating 90% sensitivity and 100% specificity compared to RT-PCR with a sample-to-answer time of 50 minutes. SHINE has the potential to be used outside of hospitals and clinical laboratories, greatly enhancing diagnostic capabilities.
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies Language: En Journal: BioRxiv Year: 2020 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies Language: En Journal: BioRxiv Year: 2020 Document type: Article Affiliation country: